Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Taxes (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Current Taxes for 12 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Current Taxes fell 77.04% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 77.04% year-over-year, with the annual reading at $1.3 million for FY2025, 77.04% down from the prior year.
  • Current Taxes hit $1.3 million in Q4 2025 for Ani Pharmaceuticals, down from $3.3 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $14.2 million in Q1 2025 to a low of $594000.0 in Q3 2023.
  • Historically, Current Taxes has averaged $6.0 million across 4 years, with a median of $4.6 million in 2021.
  • Biggest YoY gain for Current Taxes was 24.43% in 2025; the steepest drop was 77.04% in 2025.
  • Year by year, Current Taxes stood at $3.7 million in 2021, then skyrocketed by 123.12% to $8.2 million in 2023, then crashed by 31.14% to $5.6 million in 2024, then tumbled by 77.04% to $1.3 million in 2025.
  • Business Quant data shows Current Taxes for ANIP at $1.3 million in Q4 2025, $3.3 million in Q2 2025, and $14.2 million in Q1 2025.